Methotrexat Ebewe

Methotrexate, the active ingredient in Methotrexat Ebewe, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intrathecal administration. It is used to treat certain cancers, autoimmune disorders, and ectopic pregnancy in adult patients. The formulation is supplied in single‑dose vials that comply with EU pharmacopeial standards, allowing precise dosing by healthcare professionals.

GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company ensures batch‑to‑batch consistency, regulatory compliance, and reliable logistics where required.

Methotrexate is employed across several disease categories where inhibition of folate metabolism is therapeutic.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: limits skin cell proliferation and improves plaque appearance. Acute lymphoblastic leukemia: interferes with malignant lymphoblast replication. Non‑Hodgkin lymphoma: induces cytotoxicity in rapidly dividing lymphoma cells. Breast cancer: acts as an adjuvant to inhibit tumor growth. Ectopic pregnancy: halts trophoblastic tissue development to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral ulcers or mucositis. - Elevated liver enzymes. - Mild decreases in blood cell counts. - Alopecia (hair thinning).

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia. - Hepatotoxicity with potential fibrosis or cirrhosis. - Pulmonary toxicity, including interstitial pneumonitis. - Acute renal failure. - Life‑threatening infections due to immunosuppression.

When using methotrexate, several safety considerations should be observed.

Pregnancy contraindication: avoid use in women who are pregnant or may become pregnant (Category X). Liver monitoring: perform baseline and periodic liver function tests. Blood count surveillance: regularly assess complete blood counts for cytopenias. Renal function: adjust dosing or avoid in patients with significant renal impairment. Live vaccines: do not administer concurrently due to immunosuppression risk. Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methotrexate can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity and gastrointestinal ulceration. - Trimethoprim: additive bone‑marrow suppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Penicillins and cephalosporins: may reduce renal clearance of methotrexate. - Sulfonamides: potential increase in methotrexate plasma levels. - Antacids containing aluminum or calcium: can impair oral absorption if taken concurrently.